Declarations:
Consent for publication: Written informed consent was obtained from the patient for publication of this case report and the accompanying image. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.
Availability of data and materials: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Competing interests: None to be declared.
Funding statement: This article did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author contribution statement: Almurtada Razok and Abdullah Shams performed literature review and wrote the original draft of the manuscript. Ahmed Almeer and Muhammad Zahid supervised the writing process and revised the manuscript. All authors approved the final version for submission.
Acknowledgements: Open access funding was provided by Qatar National Library (QNL).
References :
[1] Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology . 2011;36(2):123-133. doi:10.1159/000324710
[2] Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet . 2016;388(10045):717-727. doi:10.1016/S0140-6736(16)00339-1
[3] Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med . 2021;27(2):205-211. doi:10.1038/s41591-021-01230-y
[4] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med . 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
[5] Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol . 1979;110(2):105-123. doi:10.1093/oxfordjournals.aje.a112795
[6]. Walling AD, Dickson G. Guillain-Barré syndrome. Am Fam Physician . 2013;87(3):191-197.
[7]. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology . 2008;70(18):1608-1613. doi:10.1212/01.wnl.0000310983.38724.d4
[8]. Bogliun G, Beghi E; Italian GBS Registry Study Group. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand . 2004;110(2):100-106. doi:10.1111/j.1600-0404.2004.00272.x
[9]. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol . 2008;7(10):939-950. doi:10.1016/S1474-4422(08)70215-1
[10]. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet . 2005;366(9497):1653-1666. doi:10.1016/S0140-6736(05)67665-9
[11]. Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine . 2007;25(29):5253-5255. doi:10.1016/j.vaccine.2007.03.053
[12]. Tuttle J, Chen RT, Rantala H, Cherry JD, Rhodes PH, Hadler S. The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States. Am J Public Health . 1997;87(12):2045-2048. doi:10.2105/ajph.87.12.2045
[13]. Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Saf . 2009;32(4):309-323. doi:10.2165/00002018-200932040-00005
[14]. Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus . 2021;13(2):e13426. Published 2021 Feb 18. doi:10.7759/cureus.13426
Figures and captions :
Figure 1:
Magnetic resonance image of the spine with intravenous gadolinium showing bilateral contrast enhancement of the nerve roots in the lumbar region and the upper part of the cauda equina (as indicated by the arrows).